Larimar Therapeutics (LRMR) Other Operating Expenses (2019 - 2020)

Larimar Therapeutics' (LRMR) quarterly Other Operating Expenses came in at -$10000.0 in Q1 2020, up 97.57% on a QoQ basis from -$411000.0 in Q4 2019.

Larimar Therapeutics (LRMR) Other Operating Expenses (2019 - 2020) Analysis & Trends

Larimar Therapeutics (LRMR) has 2 years of Other Operating Expenses data on file, last reported at -$10000.0 in Q1 2020.

Quarterly Other Operating Expenses changed N/A year-over-year to -$10000.0 in Q1 2020, while the trailing twelve-month figure through Dec 2020 was -$10000.0 (up 99.77% YoY) and the FY2019 annual result came in at -$5.6 million, changed N/A from the prior year.
Other Operating Expenses grew to -$10000.0 in Q1 2020, from -$411000.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of -$10000.0 in Q1 2020 to a low of -$4.0 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Larimar Therapeutics	452.93 Mn	296.66 Mn	-

Download Data